King's College London pCAR T-Cell Patent US12612445B2
Summary
US Patent 12,612,445 B2 granted April 28, 2026 to King's College London, London, United Kingdom, covering immunoresponsive cells such as T-cells engineered with parallel chimeric activating receptors (pCAR) comprising second-generation chimeric antigen receptors and chimeric costimulatory receptors for therapeutic applications. Filed September 22, 2023 with five claims. The pCAR architecture includes distinct binding elements targeting separate epitopes on target antigens, enabling enhanced cell therapy with kits and methods for preparation and use.
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
US Patent 12,612,445 B2 has been granted to King's College London, covering immunoresponsive cells (such as T-cells) engineered with a parallel chimeric activating receptor (pCAR) architecture. The pCAR comprises a second-generation chimeric antigen receptor (CAR) with signalling, co-stimulatory, and transmembrane regions plus a binding element for a first epitope, alongside a distinct chimeric costimulatory receptor with a different co-stimulatory signalling region, transmembrane domain, and binding element for a second epitope. Kits and methods for preparing and using these cells are also covered.
Biopharmaceutical companies and research institutions developing CAR-T or related cell therapy platforms should review this grant for potential overlap with their own IP portfolios or freedom-to-operate positions. The five claims cover a specific dual-receptor architecture not previously disclosed, which may inform next-generation CAR design strategies.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Therapeutic agents
Grant US12612445B2 Kind: B2 Apr 28, 2026
Assignee
King's College London
Inventors
John Maher, Daniela Yordanova Achkova, Lynsey May Whilding, Benjamin Owen Draper
Abstract
An immunoresponsive cell, such as a T-cell expressing
(i) a second generation chimeric antigen receptor comprising:
(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; and
(ii) a chimeric costimulatory receptor comprising
(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.
This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
CPC Classifications
C07K 14/7051 A61K 40/11 A61K 40/31 C12N 5/0636
Filing Date
2023-09-22
Application No.
18472441
Claims
5
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.